title: Effects of carprofen, meloxicam and deracoxib on platelet function in dogs.
abstract: OBJECTIVE
  To determine effects of anti-inflammatory doses of COX-2 selective NSAIDs carprofen, meloxicam, and deracoxib on platelet function in dogs and urine 11-dehydro-thromboxane B2.
  
  
  METHODS
  Randomized, blocked, crossover design with a 14-day washout period.
  
  
  METHODS
  Healthy intact female Walker Hounds aged 1-6 years and weighing 20.5-24.2 kg.
  
  
  METHODS
  Dogs were given NSAIDs for 7 days at recommended doses: carprofen (2.2 mg kg(-1), PO, every 12 hours), carprofen (4.4 mg kg(-1), PO, every 24 hours), meloxicam (0.2 mg kg(-1), PO, on the 1st day then 0.1 mg kg(-1), PO, every 24 hours), and deracoxib (2 mg kg(-1), PO, every 24 hours). Collagen/epinephrine and collagen/ADP PFA-100 cartridges were used to evaluate platelet function before and during and every other day after administration of each drug. Urine 11-dehydro-thromboxane B(2) was also measured before and during administration of each drug.
  
  
  RESULTS
  All NSAIDs significantly prolonged PFA-100 closure times when measured with collagen/epinephrine cartridges, but not with collagen/ADP cartridges. The average duration from drug cessation until return of closure times (collagen/epinephrine cartridges) to baseline values was 11.6, 10.6, 11 and 10.6 days for carprofen (2.2 mg kg(-1) every 12 hours), carprofen (4.4 mg kg(-1) every 24 hours), meloxicam and deracoxib, respectively.
  
  
  CONCLUSIONS
  Oral administration of some COX-2 selective NSAIDs causes detectable alterations in platelet function in dogs. As in humans, PFA-100 collagen/ADP cartridges do not reliably detect COX-mediated platelet dysfunction in dogs. Individual assessment of platelet function is advised when administering these drugs prior to surgery, particularly in the presence of other risk factors for bleeding.
authors.affiliation: Department of Clinical Sciences, College of Veterinary Medicine, Mississippi State University, Mississippi State, MS, USA. kathleen.mullinsdvm@vrrh.net
authors.forename: Kathleen B
authors.initials: KB
authors.lastname: Mullins
authors.forename: John M
authors.initials: JM
authors.lastname: Thomason
authors.forename: Kari V
authors.initials: KV
authors.lastname: Lunsford
authors.forename: Lesya M
authors.initials: LM
authors.lastname: Pinchuk
authors.forename: Vernon C
authors.initials: VC
authors.lastname: Langston
authors.forename: Robert W
authors.initials: RW
authors.lastname: Wills
authors.forename: Ronald M
authors.initials: RM
authors.lastname: McLaughlin
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Mackin
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D001792:Blood Platelets / Q000187:drug effects*; D002227:Carbazoles / Q000494:pharmacology*; D004285:Dogs; D005260:Female; D006487:Hemostasis / Q000187:drug effects; D000077239:Meloxicam; D010974:Platelet Aggregation / Q000187:drug effects; D013449:Sulfonamides / Q000494:pharmacology*; D013843:Thiazines / Q000494:pharmacology*; D013844:Thiazoles / Q000494:pharmacology*; D013929:Thromboxane B2 / Q000031:analogs & derivatives / Q000652:urine; D000096926:Benzenesulfonamides
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D002227:Carbazoles; D000077239:Meloxicam; D013449:Sulfonamides; D013843:Thiazines; D013844:Thiazoles; D013929:Thromboxane B2; C049235:11-dehydro-thromboxane B2; C007005:carprofen; C471996:deracoxib; D000096926:Benzenesulfonamides